JP2012512901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512901A5 JP2012512901A5 JP2011542484A JP2011542484A JP2012512901A5 JP 2012512901 A5 JP2012512901 A5 JP 2012512901A5 JP 2011542484 A JP2011542484 A JP 2011542484A JP 2011542484 A JP2011542484 A JP 2011542484A JP 2012512901 A5 JP2012512901 A5 JP 2012512901A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- seq
- sequence
- general structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 34
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 108010016626 Dipeptides Proteins 0.000 claims 29
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 235000014304 histidine Nutrition 0.000 claims 23
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 23
- 125000004429 atom Chemical group 0.000 claims 22
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 21
- 229910052799 carbon Inorganic materials 0.000 claims 21
- 239000004026 insulin derivative Substances 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 18
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 17
- 235000001014 amino acid Nutrition 0.000 claims 17
- 150000001413 amino acids Chemical group 0.000 claims 17
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 15
- 239000004473 Threonine Substances 0.000 claims 15
- 229940024606 amino acid Drugs 0.000 claims 15
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 14
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 claims 14
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 11
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 11
- 235000004279 alanine Nutrition 0.000 claims 11
- 239000004471 Glycine Substances 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 9
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 7
- VBOQYPQEPHKASR-VKHMYHEASA-N L-homocysteic acid Chemical compound OC(=O)[C@@H](N)CCS(O)(=O)=O VBOQYPQEPHKASR-VKHMYHEASA-N 0.000 claims 7
- 235000003704 aspartic acid Nutrition 0.000 claims 7
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 7
- 235000013922 glutamic acid Nutrition 0.000 claims 7
- 239000004220 glutamic acid Substances 0.000 claims 7
- 239000004472 Lysine Substances 0.000 claims 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 235000009582 asparagine Nutrition 0.000 claims 4
- 229960001230 asparagine Drugs 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 3
- 239000000539 dimer Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- OAMLVOVXNKILLQ-UHFFFAOYSA-N aspartyl-lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CC(O)=O OAMLVOVXNKILLQ-UHFFFAOYSA-N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000003827 glycol group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 0 CC(C(*c1ccc(*)cc1)NC)=O Chemical compound CC(C(*c1ccc(*)cc1)NC)=O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13921808P | 2008-12-19 | 2008-12-19 | |
| US61/139,218 | 2008-12-19 | ||
| PCT/US2009/068716 WO2010080609A1 (en) | 2008-12-19 | 2009-12-18 | Amide-based insulin prodrugs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012512901A JP2012512901A (ja) | 2012-06-07 |
| JP2012512901A5 true JP2012512901A5 (enExample) | 2013-02-21 |
| JP5755566B2 JP5755566B2 (ja) | 2015-07-29 |
Family
ID=42316748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542484A Expired - Fee Related JP5755566B2 (ja) | 2008-12-19 | 2009-12-18 | アミド系インスリンプロドラッグ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8697632B2 (enExample) |
| EP (1) | EP2376521B1 (enExample) |
| JP (1) | JP5755566B2 (enExample) |
| CN (1) | CN102245624B (enExample) |
| AU (1) | AU2009335715B2 (enExample) |
| CA (1) | CA2744558A1 (enExample) |
| WO (1) | WO2010080609A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| AU2009260302B2 (en) | 2008-06-17 | 2014-10-23 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| KR20110126592A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| CA2747109A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| MX2011006315A (es) | 2008-12-15 | 2011-09-22 | Zealand Pharma As | Analogos de glucagon. |
| KR20110126591A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| SG172291A1 (en) | 2008-12-19 | 2011-07-28 | Univ Indiana Res & Tech Corp | Amide based glucagon superfamily peptide prodrugs |
| BRPI1014508A2 (pt) | 2009-06-16 | 2016-04-05 | Univ Indiana Res & Tech Corp | análogos de peptídeo de glucagon, dimer de dois peptídeos de glucagon, composição farmacêutica deles derivada e métodos para seu uso" |
| HUE026255T2 (en) | 2009-07-13 | 2016-06-28 | Zealand Pharma As | Acylated glucagon analogues |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| AP2013006671A0 (en) | 2010-06-24 | 2013-01-31 | Zealand Pharma As | Glucagon analogues |
| CN103119057B (zh) | 2010-06-24 | 2016-06-15 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰岛素前药 |
| WO2011162968A1 (en) * | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Dipeptide linked medicinal agents |
| PH12013501495A1 (en) | 2011-01-20 | 2013-09-16 | Zealand Pharma As | Combination of acylated glucagon analogues with insulin analogues |
| WO2012123519A2 (en) * | 2011-03-15 | 2012-09-20 | Novo Nordisk A/S | Human insulin analogues and derivatives comprising cysteine substitutions |
| JP6058646B2 (ja) | 2011-06-15 | 2017-01-11 | ノヴォ ノルディスク アー／エス | 多置換インスリン |
| CN103857408B (zh) | 2011-06-22 | 2017-04-12 | 印第安那大学科技研究公司 | 胰高血糖素/glp‑1受体协同激动剂 |
| WO2013096386A1 (en) | 2011-12-20 | 2013-06-27 | Indiana University Research And Technology Corporation | Ctp-based insulin analogs for treatment of diabetes |
| JP6228187B2 (ja) | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| MY170671A (en) | 2012-07-23 | 2019-08-26 | Zealand Pharma As | Glucagon analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| WO2014052451A2 (en) | 2012-09-26 | 2014-04-03 | Indiana University Research And Technology Corporation | Insulin analog dimers |
| WO2014088836A1 (en) | 2012-12-03 | 2014-06-12 | Merck Sharp & Dohme Corp. | O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues |
| EP2931301B2 (en) | 2012-12-17 | 2021-09-15 | Merck Sharp & Dohme Corp. | Process for purifying insulin and analogues thereof |
| JP6538645B2 (ja) * | 2013-03-14 | 2019-07-03 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン‐インクレチン複合物 |
| US9884125B2 (en) | 2013-10-04 | 2018-02-06 | Merck Sharp & Dohme Corp. | Glucose-responsive insulin conjugates |
| CA2926314C (en) | 2013-10-17 | 2023-08-29 | Zealand Pharma A/S | Acylated glucagon analogues |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
| BR112016009889B1 (pt) | 2013-11-06 | 2023-11-28 | Zealand Pharma A/S | Análogo do gip, composição farmacêutica compreendendo um análogo do gip, ou um sal farmaceuticamente aceitável do mesmo, e seu uso |
| EP3077414B1 (en) | 2013-12-04 | 2020-06-17 | Merck Sharp & Dohme Corp. | Method for preparing crystalline insulin |
| EP3077008B1 (en) | 2013-12-06 | 2023-10-04 | Jie Han | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
| AU2015206890B2 (en) | 2014-01-20 | 2019-05-23 | Hanmi Pharm. Co., Ltd. | Long-acting insulin and use thereof |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| US10407483B2 (en) | 2014-03-14 | 2019-09-10 | Merck Sharp & Dohme Corp. | Purifying insulin using cation exchange and reverse phase chromatography in the presence of an organic modifier and elevated temperature |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| EP3171888B1 (en) | 2014-07-21 | 2022-12-28 | Merck Sharp & Dohme LLC | Chromatography process for purification of inlsulin and insulin analogs |
| WO2016049190A1 (en) | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| CN107001441A (zh) | 2014-09-24 | 2017-08-01 | 印第安纳大学研究及科技有限公司 | 脂质化的基于酰胺的胰岛素前药 |
| DK3212218T3 (da) | 2014-10-29 | 2021-08-30 | Zealand Pharma As | GIP-agonistforbindelser og fremgangsmåder |
| SG10201809428UA (en) | 2014-11-21 | 2018-11-29 | Merck Sharp & Dohme | Insulin receptor partial agonists |
| US10562951B2 (en) | 2015-03-10 | 2020-02-18 | Merck Sharp & Dohme Corp. | Process for preparing recombinant insulin using microfiltration |
| WO2016166289A1 (en) | 2015-04-16 | 2016-10-20 | Zealand Pharma A/S | Acylated glucagon analogue |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| US10745457B2 (en) | 2015-09-02 | 2020-08-18 | Merck Sharp & Dohme Corp. | Process for obtaining insulin with correctly formed disulfide bonds |
| WO2017180988A2 (en) | 2016-04-15 | 2017-10-19 | Indiana University Research And Technology Corporation | Fgf21 c-terminal peptide optimization |
| EP3448417B1 (en) | 2016-04-26 | 2025-11-12 | Merck Sharp & Dohme LLC | Insulin dimer-incretin conjugates |
| WO2017205191A1 (en) | 2016-05-24 | 2017-11-30 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists and glp-1 analogues |
| WO2017205309A1 (en) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists |
| PL3464336T3 (pl) | 2016-06-01 | 2022-05-16 | Athira Pharma, Inc. | Związki |
| WO2017210168A1 (en) * | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Aqueously soluble and chemically stable depsi glucagon agonists |
| EP3272877A1 (en) | 2016-07-18 | 2018-01-24 | ETH Zurich | B-cell-mimetic cells |
| CA3030642A1 (en) | 2016-07-18 | 2018-01-25 | Eth Zurich | B-cell-mimetic cells |
| KR102698929B1 (ko) | 2016-09-23 | 2024-08-27 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도 |
| TW201835099A (zh) | 2017-03-07 | 2018-10-01 | 美國凱斯西方瑞瑟夫大學 | 藉由第四雙硫鍵穩定之單鏈胰島素類似物 |
| WO2018175272A1 (en) | 2017-03-23 | 2018-09-27 | Merck Sharp & Dohme Corp. | Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes |
| MX2019011297A (es) | 2017-03-23 | 2019-11-12 | Hanmi Pharm Ind Co Ltd | Complejo de analogo de insulina con afinidad reducida por el receptor de insulina y uso del mismo. |
| EP3624828B1 (en) | 2017-05-18 | 2024-08-07 | Merck Sharp & Dohme LLC | Pharmaceutical formulation comprising incretin-insulin conjugates |
| TW201917134A (zh) | 2017-08-17 | 2019-05-01 | 丹麥商諾佛 儂迪克股份有限公司 | 新穎的醯基化胰島素類似物及其用途 |
| SG11202106167XA (en) | 2018-12-11 | 2021-07-29 | Sanofi Sa | Insulin conjugates |
| US12427187B2 (en) | 2019-06-06 | 2025-09-30 | Merck Sharp & Dohme Llc | Glucose-responsive insulin conjugates |
| IL298338A (en) * | 2020-05-26 | 2023-01-01 | Univ Indiana Res & Tech Corp | Pth analogs for the treatment of hypoparathyroidism |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3740385A (en) | 1970-05-07 | 1973-06-19 | M Ondetti | N-terminal derivatives of secretin |
| US4275152A (en) | 1977-02-03 | 1981-06-23 | Eastman Kodak Company | Hydrolysis of protein-bound cholesterol esters |
| PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4741897A (en) | 1986-07-08 | 1988-05-03 | Baxter Travenol | Thyroxine analogs and reagents for thyroid hormone assays |
| US4876242A (en) | 1987-09-21 | 1989-10-24 | Merck & Co., Inc. | Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast |
| GB8728561D0 (en) | 1987-12-07 | 1988-01-13 | Glaxo Group Ltd | Chemical compounds |
| US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| EP0469084B1 (en) * | 1989-04-20 | 1995-04-05 | Mount Sinai School Of Medicine Of The City University Of New York | Hepatospecific insulin analogues |
| US5268453A (en) | 1991-08-08 | 1993-12-07 | Scios Inc. | Tissue-selective insulin analogs |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6476290B1 (en) | 1995-04-19 | 2002-11-05 | Dalhousie University | Transgenic tilapia comprising a humanized insulin gene |
| EP0741188A3 (en) | 1995-05-05 | 1999-07-14 | Eli Lilly And Company | Single chain insulin with high bioactivity |
| US6180767B1 (en) | 1996-01-11 | 2001-01-30 | Thomas Jefferson University | Peptide nucleic acid conjugates |
| CA2265454A1 (en) | 1996-09-09 | 1998-03-19 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| PL342517A1 (en) | 1998-02-23 | 2001-06-18 | Neurocrine Biosciences | Methods of treating diabetes employing peptidic insulin analoques |
| EP1950223A3 (en) | 1998-03-09 | 2009-05-13 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| US6875741B2 (en) | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
| US20030236190A1 (en) | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
| DE19908041A1 (de) | 1999-02-24 | 2000-08-31 | Hoecker Hartwig | Kovalent verbrückte Insulindimere |
| US6921748B1 (en) | 1999-03-29 | 2005-07-26 | Uutech Limited | Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes |
| US6746853B1 (en) | 1999-05-19 | 2004-06-08 | Xencor, Inc. | Proteins with insulin-like activity useful in the treatment of diabetes |
| AUPQ661800A0 (en) | 2000-03-31 | 2000-05-04 | Metabolic Pharmaceuticals Limited | Insulin-potentiating compounds |
| CN1454214A (zh) | 2000-08-02 | 2003-11-05 | 赛莱技术公司 | 具有增高功效的修饰生物肽 |
| WO2002012201A1 (en) | 2000-08-04 | 2002-02-14 | Dmi Biosciences, Inc. | Method of synthesizing diketopiperazines |
| EP2295450B1 (en) | 2000-09-29 | 2015-01-28 | Merck Sharp & Dohme Corp. | Pegylated interleukin-10 |
| KR100449454B1 (ko) | 2000-10-02 | 2004-09-21 | 이현철 | 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터 |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| DK2322631T3 (en) | 2001-04-19 | 2015-01-12 | Scripps Research Inst | Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar |
| US20050014679A1 (en) * | 2001-12-20 | 2005-01-20 | Beals John Michael | Insulin molecule having protracted time action |
| GB2392994A (en) * | 2002-05-30 | 2004-03-17 | Medivance Instr Ltd | Apparatus and method for monitoring the efficacy of an X-ray or photographic development process |
| FR2842209B1 (fr) * | 2002-07-09 | 2007-11-23 | Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique | |
| AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20050059605A1 (en) | 2003-01-31 | 2005-03-17 | Krishna Peri | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| WO2004078777A2 (en) | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
| EP1605897B1 (en) | 2003-03-19 | 2012-07-25 | Eli Lilly And Company | Polyethelene glycol link glp-1 compounds |
| EP1620118B1 (en) | 2003-04-08 | 2014-06-18 | Yeda Research And Development Co., Ltd. | Reversible pegylated drugs |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| KR101241862B1 (ko) | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| WO2005035003A2 (en) | 2003-09-22 | 2005-04-21 | Dihedron Corporation | Compositions and methods for increasing drug efficiency |
| ES2437567T3 (es) | 2003-11-05 | 2014-01-13 | Dana-Farber Cancer Institute, Inc. | Péptidos alfa helicoidales estabilizados y utilizaciones de los mismos |
| AU2004295023A1 (en) | 2003-12-03 | 2005-06-16 | Novo Nordisk A/S | Single-chain insulin |
| JP2008517917A (ja) | 2004-10-21 | 2008-05-29 | アイジーエフ オンコロジー エルエルシー | 癌を治療するための毒素および放射性核種結合ｉｇｆ−１受容体リガンド |
| US7521211B2 (en) | 2005-04-05 | 2009-04-21 | Regeneron Pharmaceuticals, Inc | IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof |
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| EP1991575A1 (en) * | 2006-02-21 | 2008-11-19 | Novo Nordisk A/S | Single-chain insulin analogues and pharmaceutical formulations thereof |
| ES2397659T3 (es) | 2006-03-15 | 2013-03-08 | Novo Nordisk A/S | Mezclas de amilina e insulina |
| AU2007284365A1 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
| MX2009002523A (es) | 2006-09-08 | 2009-03-20 | Ambrx Inc | Polipeptido de plasma humano modificado o andamios fc y sus usos. |
| CN103298935A (zh) | 2007-08-15 | 2013-09-11 | 阿穆尼克斯公司 | 用于改善生物活性多肽性能的组合物和方法 |
| EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| CA2703830A1 (en) | 2007-11-20 | 2009-05-28 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| JP2011511778A (ja) | 2008-01-30 | 2011-04-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | エステルに基づいたペプチドプロドラッグ |
| DK2596805T3 (da) | 2008-02-01 | 2021-12-13 | Ascendis Pharma As | Prodrug omfattende et lægemiddel-linker-konjugat |
| WO2010011313A2 (en) | 2008-07-23 | 2010-01-28 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
| MX2011006527A (es) | 2008-12-19 | 2011-08-17 | Univ Indiana Res & Tech Corp | Agentes medicinales unidos a dipeptido. |
| SG172291A1 (en) | 2008-12-19 | 2011-07-28 | Univ Indiana Res & Tech Corp | Amide based glucagon superfamily peptide prodrugs |
| CN103179979A (zh) | 2010-06-24 | 2013-06-26 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
-
2009
- 2009-12-18 CN CN200980151543.0A patent/CN102245624B/zh not_active Expired - Fee Related
- 2009-12-18 JP JP2011542484A patent/JP5755566B2/ja not_active Expired - Fee Related
- 2009-12-18 AU AU2009335715A patent/AU2009335715B2/en not_active Ceased
- 2009-12-18 US US13/130,966 patent/US8697632B2/en not_active Expired - Fee Related
- 2009-12-18 EP EP09837985.2A patent/EP2376521B1/en not_active Not-in-force
- 2009-12-18 WO PCT/US2009/068716 patent/WO2010080609A1/en not_active Ceased
- 2009-12-18 CA CA2744558A patent/CA2744558A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012512901A5 (enExample) | ||
| JP2011511778A5 (enExample) | ||
| JP2013533864A5 (enExample) | ||
| JP5683951B2 (ja) | 長期間作用性ペプチド類似体のための組成物 | |
| JP2013540102A5 (enExample) | ||
| JP2015532283A5 (enExample) | ||
| JP2011511753A5 (enExample) | ||
| JP2019526537A5 (enExample) | ||
| WO2019117274A1 (ja) | ペプチドの製造方法、及び塩基の処理方法 | |
| JP2017534675A5 (enExample) | ||
| RU2014127270A (ru) | Аналог человеческого инсулина и его ацилированное производное | |
| JP2017534676A5 (enExample) | ||
| JP2010515686A5 (enExample) | ||
| RU2013103093A (ru) | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкаганов | |
| RU2008143668A (ru) | Производное инсулина | |
| JP2013511554A5 (enExample) | ||
| JP2022095872A5 (enExample) | ||
| JP2016523241A5 (enExample) | ||
| JP6633523B2 (ja) | Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体 | |
| JP2009532384A5 (enExample) | ||
| JP2010504934A5 (enExample) | ||
| JP2013531660A5 (enExample) | ||
| JP2017534675A (ja) | 脂質化アミド系インスリンプロドラッグ | |
| RU2013146690A (ru) | Циклические пептиды с антинеопластической и антиангионенной активностью | |
| ES2308539T3 (es) | Ciclacion de peptidos. |